In an effort aimed to ensure patients worldwide affected by immune-mediated diseases can benefit from cutting-edge innovations, Johnson & Johnson is proud to launch the Leveraging Technology to Drive Representative Clinical Trials QuickFire Challenge. Innovators from around the globe are invited to submit tools, platforms, technologies, or methods to enhance diversity, equity, and inclusion in clinical studies with the goal to increase patient representation* for global clinical trials focused on immune- mediated diseases.
The innovator(s) with the best potential solution(s) will receive grant funding from a total pool of up to $250,000, access to the global Johnson & Johnson Innovation – JLABS network, and mentorship from experts across Johnson & Johnson for one year.
Applications should be aimed at advancing healthcare innovation within Johnson & Johnson Immunology priority focus areas. Specific disease areas of interest include:
Inflammatory bowel disease (ulcerative colitis and Crohn's disease), rheumatology diseases (rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus and Sjögren’s disease (SjD), dermatology diseases (psoriasis, atopic dermatitis, and hidradenitis suppurativa) and maternal-fetal autoantibody diseases (Hemolytic disease of the fetus and newborn and Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)). Platform approaches with potential applicability within these areas are also in scope.
Expires on September 14, 2024
Més posts de Concursos
Comentaris